Bankruptcy Bid: XNK Therapeutics

XNK Therapeutics AB was declared bankrupt on April 9, 2024. The Södertörns District Court appointed Anders Svensson Clark as bankruptcy trustee.

XNK Therapeutics is a clinical-stage biotechnology company developing unique and individualized natural killer cell-based cancer therapies.

If you wish to submit a bid on the company’s business and/or assets, please contact anders.svensson.clark@se.dlapiper.com and therese.isaksson@se.dlapiper.com.

Update

On 6 May 2024, the bankruptcy estate sold the GMP facility referred to in the information memorandum together with the assets located in the GMP facility and transferred the lease agreement for the GMP facility to the new tenant. The bankruptcy estate is now seeking to sell the patents and the intellectual property (IP) developed by XNK Therapeutics AB.

Any bids on the IP should be submitted no later than 31 May 2024. Please review the information memorandum to find further information regarding the IP.